Dr. Jongseong Kim is the Founder and CEO of OncoLab Co., Ltd., a Deep Tech biotechnology company developing ANGel, an advanced nanogel-based platform that integrates precision drug delivery with localized immunotherapy. He received his Ph.D. in Chemistry from the Georgia Institute of Technology and completed postdoctoral training in immunology at Harvard Medical School. Dr. Kim has extensive research experience in the design of bioresponsive nanomaterials and hydrogel-based drug delivery systems, with a focus on modulating immune responses within the tumor microenvironment. His work has centered on engineering surface-functionalized nanoparticles capable of delivering immune checkpoint inhibitors and other biologics in a sustained and tumor-targeted manner, minimizing systemic toxicity while enhancing therapeutic efficacy. At OncoLab, Dr. Kim leads the development of ANGel as a modular platform for combination immunotherapy, currently targeting triple-negative breast cancer and other solid tumors. He is overseeing the preclinical development program, including GLP-compliant toxicology studies and IND-enabling activities, while actively engaging with global pharmaceutical partners to explore co-development and licensing opportunities. His long-term vision is to translate platform-based immunoengineering innovations into clinically impactful therapies for hard-to-treat cancers.